文献速递淋巴瘤

Hi-C测序在大B细胞淋巴瘤基因重排检测中的应用

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

本研究对159例DLBCL患者的FFPE组织进行Hi-C测序,在92例中检出102个MYC、BCL2和/或BCL6重排,并发现25个FISH漏检的重排。20例(12.6%)检出其他淋巴瘤类型特征性重排,机器学习分析识别出多个具有显著预后影响的重排。

要点

  • Hi-C测序可一次性检测全基因组重排,补充FISH漏检的临床重要重排。
  • Hi-C检出CCND1等重排可提示其他淋巴瘤类型,辅助诊断分型。
  • 基于机器学习的全基因组重排分析可识别具有预后意义的重排。

核心结论

  • Hi-C测序能以无偏倚的分子方式检测对DLBCL诊断至关重要的基因重排,在本研究中显示出高灵敏度和特异度。

研究设计与样本

  • 本研究采用Hi-C测序对159例DLBCL患者的福尔马林固定石蜡包埋组织进行检测。

主要发现

  • Hi-C在重排断点处或附近共识别746个癌症基因,总发生次数为1903次。
  • Hi-C在92例患者中检出102个MYC、BCL2和/或BCL6重排,并揭示融合伴侣,包括25个FISH漏检的重排。
  • FISH假阴性原因包括FISH隐匿性断点、复杂或微弱FISH信号、FISH阳性百分比低及组织固定相关问题。
  • 20例患者(12.6%)中Hi-C检出22个其他淋巴瘤类型特征性重排,包括可导致重新分类为套细胞淋巴瘤的CCND1重排。
  • 基于机器学习模型的全基因组重排生存分析识别出MYC、PD-L1、CCND1、BCL2、NTRK1/PRCC、RRAS和FANCE重排在该DLBCL队列中具有显著预后影响。

临床怎么用

  • Hi-C测序可改善临床病理实验室工作流程、诊断精确性和大B细胞淋巴瘤的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, arises from various pathogenic mechanisms, including gene translocations and fusions. Detection of gene rearrangements using fluorescence in situ hybridization (FISH) is a standard practice for DLBCL diagnosis and guides treatment decisions. High-throughput chromosome conformation capture (Hi-C) DNA sequencing is a next-generation sequencing-based technology to identify genome-wide rearrangements using a single assay. In this study, Hi-C sequencing was performed using formalin-fixed paraffin-embedded tissues from 159 patients with DLBCL, identifying 746 cancer genes at or proximal to the rearrangement breakpoints, with a total of 1903 occurrences. Focusing on clinically important rearrangements, Hi-C detected 102 rearrangements of MYC, BCL2, and/or BCL6 in 92 patients and revealed the fusion partners, including 25 rearrangements missed by FISH. Causes of FISH-negative results included FISH-cryptic breakpoints, complex or faint FISH signals, low percentage of FISH positivity, and issues related to tissue fixation. Moreover, in 20 patients (12.6%), Hi-C sequencing detected 22 rearrangements characteristic of other lymphoma types, including CCND1 rearrangements that could lead to reclassification as mantle cell lymphoma. Survival analysis of genome-wide rearrangements using machine learning models identified MYC, PD-L1, CCND1, BCL2, NTRK1/PRCC, RRAS, and FANCE rearrangements with significant prognostic effects in the DLBCL cohort. In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Xu-Monette ZY, Wang C, Wu D, et al. Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood Adv. 2026. PMID: 42308239. doi:10.1182/bloodadvances.2026019675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。